Tag: NOVEL

  • Alpha-Klotho

    Type I transmembrane protein and circulating endocrine factor of the glycosyl hydrolase family 1 superfamily with obligate FGF23 co-receptor and pleiotropic anti-aging functions

    A kidney-derived transmembrane glycoprotein and its shed soluble ectodomain, identified through insertional mutagenesis in 1997 as a suppressor of aging phenotypes in mice, functioning both as an obligate co-receptor for fibroblast growth factor 23 in mineral metabolism and as a circulating endocrine factor that inhibits insulin/IGF-1, Wnt, TGF-beta, and NF-kappaB signaling pathways with demonstrated neuroprotective, cardioprotective, and renoprotective activity in preclinical models.

    Abstract

    Alpha-Klotho (alpha-KL) is a 130 kDa type I single-pass transmembrane protein encoded by the KL gene on human chromosome 13q13.1, first identified in 1997 by Kuro-o et al. through characterization of an insertional mutation in mice that produced a syndrome of accelerated aging encompassing soft tissue calcification, arteriosclerosis, skin atrophy, osteoporosis, emphysema, gonadal dysplasia, and dramatically shortened lifespan [1]. The protein comprises a short intracellular domain, a single transmembrane helix, and a large extracellular region containing two tandem glycosyl hydrolase family 1 (GH1) domains, designated KL1 and KL2, which share sequence homology with family 1 beta-glucosidases but lack catalytic activity against conventional substrates due to substitutions in the active-site residues. The extracellular domain undergoes proteolytic shedding by ADAM10, ADAM17, and BACE1, generating a soluble ectodomain (sKL) comprising KL1 and KL2 that circulates as an endocrine factor detectable in plasma, cerebrospinal fluid, and urine. A shorter secreted isoform containing only KL1 is produced by alternative mRNA splicing.

    In its membrane-bound form, alpha-Klotho functions as an obligate co-receptor for fibroblast growth factor 23 (FGF23), forming a ternary complex with FGF receptor 1c (FGFR1c) that is essential for phosphaturic signaling in the renal proximal tubule and for suppression of 1,25-dihydroxyvitamin D3 (calcitriol) synthesis. The crystal structure of the alpha-Klotho/FGFR1c/FGF23 ternary complex, resolved by Chen et al. (2018) at 3.0 angstrom resolution, demonstrated that the KL2 domain of alpha-Klotho cradles FGF23 with a receptor-binding arm extending from the KL1-KL2 interdomain cleft, creating a composite binding surface for FGF23 engagement [2]. Loss of this co-receptor function produces the hyperphosphatemia, hypervitaminosis D, and ectopic calcification that characterize the kl/kl mouse phenotype and that are recapitulated in FGF23 knockout mice.

    Independent of the FGF23 co-receptor function, soluble alpha-Klotho acts as a circulating endocrine factor with pleiotropic anti-aging activity. Characterized signaling activities include inhibition of the insulin/insulin-like growth factor 1 (IGF-1) pathway through suppression of receptor autophosphorylation; suppression of Wnt/beta-catenin signaling through direct binding to Wnt ligands; inhibition of transforming growth factor beta (TGF-beta) type II receptor signaling and downstream Smad phosphorylation; suppression of NF-kappaB-driven inflammatory transcription; and regulation of ion channel and transporter activity in the renal tubule, including TRPV5, TRPV6, ROMK1, and the Na+/K+-ATPase [3, 4, 5]. These FGF23-independent activities are the molecular basis for the broader anti-aging, neuroprotective, cardioprotective, and anti-fibrotic effects observed in gain-of-function and supplementation studies.

    Circulating soluble alpha-Klotho levels decline with age in humans, beginning approximately in the fourth decade of life, and are markedly reduced in chronic kidney disease, where loss of renal alpha-Klotho expression precedes and contributes to the mineral and bone disorder, cardiovascular calcification, and accelerated aging phenotype of uremia [6]. Epidemiological studies have identified inverse associations between circulating soluble alpha-Klotho concentrations and all-cause mortality, cardiovascular events, and cognitive decline in community-dwelling older adults [7]. The KL-VS haplotype (defined by the F352V and C370S variants, rs9536314 and rs9527025) has been associated in some cohorts with altered klotho secretion, cortical brain volume, and cognitive resilience in aging, though replication across large cohorts remains inconsistent [8, 9].

    Preclinical studies have demonstrated that recombinant alpha-Klotho protein administration, adeno-associated virus-mediated KL gene transfer, and transgenic KL overexpression produce renoprotection in ischemia-reperfusion injury and unilateral ureteral obstruction models; cardioprotection with attenuation of left ventricular hypertrophy and fibrosis; suppression of vascular calcification; and cognitive enhancement in aged, young, and alpha-synuclein transgenic mice through NMDA receptor-dependent glutamatergic mechanisms [10, 11, 12, 13]. A 2023 study in aged nonhuman primates demonstrated that a single subcutaneous injection of a klotho protein fragment enhanced spatial and working memory, representing the first primate cognitive enhancement data for the compound [14].

    As of 2026, alpha-Klotho is in early clinical development. Klothea Bio launched a Phase 1b randomized, double-blind, placebo-controlled trial of AKL003, an alpha-Klotho mRNA therapeutic administered intravenously, in healthy adult volunteers in February 2026. Klotho Neurosciences is advancing KLTO-202, a KL gene therapy, toward first-in-human studies for amyotrophic lateral sclerosis. No alpha-Klotho protein or gene therapy product has received regulatory approval in any jurisdiction. Recombinant human alpha-Klotho protein is available from multiple research suppliers (R&D Systems, Abcam, Sino Biological, Thermo Fisher) for in vitro and preclinical applications. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Pridopidine

    Selective sigma-1 receptor agonist with low-affinity dopamine D2 receptor antagonism and CYP2D6 auto-inhibition

    A 4-phenylpiperidine sigma-1 receptor agonist originally developed as a dopaminergic stabilizer, repositioned on the basis of high-affinity sigma-1 binding and neuroprotective activity in Huntington disease and amyotrophic lateral sclerosis models, with Phase 3 clinical data in Huntington disease and an FDA-cleared Phase 3 program in ALS.

    Abstract

    Pridopidine (ACR16; 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine; CAS 346688-38-8; molecular formula C15H23NO2S; molecular weight 281.41) is a selective sigma-1 receptor (S1R) agonist with a binding affinity (Ki) of approximately 57 nM at the human sigma-1 receptor and substantially lower affinity at the dopamine D2 receptor (Ki approximately 2950 nM), the dopamine D3 receptor (Ki approximately 1630 nM), the adrenergic alpha-2C receptor (Ki approximately 1580 nM), and the sigma-2 receptor (Ki approximately 5450 nM). The compound was synthesized at A. Carlsson Research (later NeuroSearch) as part of a structure-activity exploration of 4-phenylpiperidine dopamine D2 receptor ligands with fast dissociation kinetics and was originally classified as a “dopaminergic stabilizer” on the basis of its state-dependent modulation of dopaminergic tone in behavioral models. Subsequent binding, functional, and positron emission tomography studies established that the principal pharmacological target at clinically relevant concentrations is the sigma-1 receptor, an endoplasmic reticulum chaperone protein located at the mitochondria-associated membrane that regulates calcium homeostasis, mitochondrial function, brain-derived neurotrophic factor (BDNF) trafficking and secretion, endoplasmic reticulum stress responses, autophagy, and synaptic plasticity. Pridopidine has demonstrated neuroprotective and neurorestorative activity in preclinical models of Huntington disease (YAC128 transgenic mice, R6/2 mice), amyotrophic lateral sclerosis (SOD1G93A mice), Parkinson disease (6-OHDA lesioned mice), and glaucoma (optic nerve crush and microbead occlusion models), with effects dependent on sigma-1 receptor activation and abolished in sigma-1 receptor knockout animals.

    Clinical development has focused primarily on Huntington disease. The Phase 3 MermaiHD trial (437 patients, 26 weeks) did not meet its primary motor endpoint (modified Motor Score) but demonstrated nominally significant improvement on the total Unified Huntington’s Disease Rating Scale (UHDRS) Total Motor Score. The Phase 3 PROOF-HD trial (499 patients, 65 weeks) did not meet its primary endpoint (TFC change) in the overall population but demonstrated statistically significant benefit on TFC, composite UHDRS score, and multiple secondary endpoints in the pre-specified subgroup of participants not receiving antidopaminergic medications. A European Marketing Authorisation Application was submitted in 2024 for the treatment of adults with Huntington disease; the Committee for Medicinal Products for Human Use recommended refusal in July 2025, and Prilenia Therapeutics has announced plans for a confirmatory global Phase 3 study.

    In amyotrophic lateral sclerosis, pridopidine was evaluated in the Phase 2 HEALEY ALS Platform Trial (121 participants, 24 weeks). The primary endpoint (ALSFRS-R total score change) was not met in the full analysis set, but subgroup analyses in patients with early and rapidly progressive disease demonstrated a 32 percent slowing of ALSFRS-R decline, a 62 percent slowing of respiratory decline, and a prolongation of median survival from approximately 300 to 600 days. The United States Food and Drug Administration cleared a pivotal Phase 3 trial (PREVAiLS, 500 patients) in December 2025, with recruitment planned for early 2026.

    Pharmacokinetics are characterized by oral absorption, hepatic CYP2D6-mediated N-depropylation, and a single-dose elimination half-life of approximately 6 hours in extensive CYP2D6 metabolizers and 15 hours in poor metabolizers. Pridopidine is a metabolism-dependent inhibitor of CYP2D6, producing auto-inhibition that extends the effective half-life to 10 to 14 hours regardless of CYP2D6 genotype on repeated dosing, an unusual pharmacokinetic property that reduces inter-individual variability at steady state and eliminates the requirement for CYP2D6 genotype-based dose adjustment.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Beta-Lapachone

    NQO1-bioactivatable ortho-naphthoquinone with selective tumor cytotoxicity through futile redox cycling and PARP1 hyperactivation

    A naturally derived 1,2-naphthoquinone from the lapacho tree, bioactivated selectively by NAD(P)H:quinone oxidoreductase 1 to induce tumor-specific programmed necrosis through futile redox cycling, massive reactive oxygen species generation, DNA damage, PARP1 hyperactivation, and catastrophic NAD+/ATP depletion.

    Abstract

    Beta-lapachone is a naturally occurring ortho-naphthoquinone originally isolated from the heartwood of Tabebuia avellanedae (pau d’arco, lapacho) and synthesized from the prenylated naphthoquinone lapachol by acid-catalyzed cyclization. The compound is the canonical substrate of NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase, EC 1.6.5.2), a two-electron reductase that is overexpressed 5- to 100-fold in the majority of solid human cancers, including non-small cell lung, pancreatic ductal adenocarcinoma, breast, prostate, and head and neck squamous cell carcinomas, relative to matched normal tissue. NQO1-mediated two-electron reduction of beta-lapachone produces an unstable hydroquinone that spontaneously autoxidizes back to the parent quinone in a futile redox cycle consuming approximately 60 moles of NAD(P)H per mole of drug over a 2-hour exposure window. This cycle generates massive superoxide and hydrogen peroxide fluxes within the tumor cell, producing extensive oxidative DNA damage (predominantly single-strand breaks and oxidized bases) that triggers hyperactivation of poly(ADP-ribose) polymerase 1 (PARP1) in the presence of elevated nuclear calcium. PARP1 hyperactivation consumes the cellular NAD+ pool into branched poly(ADP-ribose) polymers, producing catastrophic NAD+ and ATP depletion, mu-calpain activation, apoptosis-inducing factor (AIF) translocation from mitochondria to the nucleus, and programmed necrosis that is mechanistically distinct from classical apoptosis and independent of caspase activation, p53 status, and Bcl-2 family protein expression. The NQO1 dependence of the cytotoxic mechanism confers tumor selectivity: NQO1-negative cells (including most normal tissues) are resistant to beta-lapachone at pharmacologically achievable concentrations, and dicoumarol (an NQO1 inhibitor) completely abrogates cytotoxicity in NQO1-positive cancer cell lines. Beta-lapachone was advanced into clinical development as ARQ 501 (an intravenous hydroxypropyl-beta-cyclodextrin inclusion complex) by ArQule, Inc. and subsequently as ARQ 761 (an improved intravenous formulation) by the University of Texas Southwestern Medical Center. A Phase II trial of ARQ 501 in combination with gemcitabine in treatment-naive unresectable pancreatic adenocarcinoma demonstrated disease stabilization but did not produce objective tumor responses sufficient for registration. Beyond anticancer applications, beta-lapachone exhibits anti-inflammatory activity through suppression of NF-kappaB-driven cytokine expression in activated macrophages and microglia, anti-obesity effects through stimulation of energy expenditure and white adipose tissue browning via NQO1-dependent NADH oxidation, and antimicrobial activity against Trypanosoma cruzi and Mycobacterium tuberculosis. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Blarcamesine

    Sigma-1 receptor agonist and mixed muscarinic receptor modulator (aminotetrahydrofuran derivative)

    An orally bioavailable aminotetrahydrofuran derivative developed by Anavex Life Sciences as a sigma-1 receptor agonist with muscarinic receptor co-activity, investigated for disease modification in Alzheimer’s disease, Rett syndrome, Parkinson’s disease dementia, and other neurodegenerative and neurodevelopmental conditions.

    Abstract

    Blarcamesine (ANAVEX 2-73; tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine) is a small-molecule sigma-1 receptor (SIGMAR1) agonist and mixed muscarinic acetylcholine receptor modulator that has advanced through Phase 2b/3 clinical development for early Alzheimer’s disease, Phase 3 for adult Rett syndrome, Phase 2 for Parkinson’s disease dementia, and Phase 2/3 for pediatric Rett syndrome. The compound was first characterized pharmacologically by Villard, Espallergues, Keller, Vamvakides, and Maurice (2011) as a novel aminotetrahydrofuran derivative with anti-amnesic and neuroprotective activity mediated through dual engagement of sigma-1 and muscarinic acetylcholine receptors. The sigma-1 receptor is an endoplasmic reticulum chaperone protein localized at mitochondria-associated endoplasmic reticulum membranes (MAMs) that modulates calcium homeostasis, endoplasmic reticulum stress responses, mitochondrial function, autophagy, and neuroinflammation. Activation of SIGMAR1 by blarcamesine restores cellular proteostasis, reduces oxidative stress through suppression of reactive oxygen species, and promotes neuroplasticity through downstream modulation of brain-derived neurotrophic factor and glutamate signaling. In preclinical models, blarcamesine has demonstrated anti-amnesic activity in scopolamine- and dizocilpine-induced learning impairment paradigms, neuroprotection in the amyloid-beta(25-35) peptide injection mouse model of Alzheimer’s disease (blocking both cognitive impairment and hippocampal oxidative stress), amelioration of motor, sensory, and autonomic phenotypes in the Mecp2 mouse model of Rett syndrome, and dose-dependent sigma-1 receptor occupancy confirmed by positron emission tomography with the selective ligand [18F]FTC-146. Co-primary analysis showed significant benefit on CDR-SB. Volumetric magnetic resonance imaging demonstrated significant reduction of whole brain atrophy by 37.6%, total grey matter atrophy by 63.5%, and lateral ventricular enlargement by 25.1% versus placebo. Plasma amyloid-beta 42/40 ratio increased significantly in the blarcamesine group (P = 0.048). Open-label extension data through four years of continuous treatment demonstrated sustained benefit on ADAS-Cog13 and ADCS-ADL, with a delayed-start analysis suggesting importance of early treatment initiation. A proof-of-concept Phase 2 trial in 132 patients with Parkinson’s disease dementia showed dose-dependent cognitive improvement on the CDR computerized assessment system and improvement on MDS-UPDRS total score at 14 weeks [3]. The EXCELLENCE Phase 2/3 pediatric Rett syndrome trial in 92 patients showed numerical improvement in RSBQ but did not achieve statistical separation from placebo, possibly due to a high placebo response rate [4]. The safety profile across clinical programs is characterized by predominantly mild-to-moderate adverse events concentrated during the initial dose titration period. The most common treatment-emergent adverse events are dizziness (approximately 36% of treated patients in the Alzheimer’s disease program), confusional state (approximately 14%), balance disorder, and fatigue; these are generally transient (resolving within 7 to 11 days), manageable by titration schedule adjustment, and not associated with serious or life-threatening sequelae. No neuroimaging-related adverse events (such as amyloid-related imaging abnormalities) have been reported. Long-term safety data through four years of continuous dosing have not revealed new safety signals. The European Medicines Agency accepted a Marketing Authorization Application for blarcamesine in Alzheimer’s disease in December 2024, but the Committee for Medicinal Products for Human Use issued a negative opinion in December 2025 on grounds of insufficient demonstration of efficacy in patients without SIGMAR1 gene mutations and concerns regarding tolerability-driven treatment discontinuation. The application was subsequently withdrawn in March 2026. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • LM22A-4

    Small-molecule TrkB partial agonist and BDNF loop-domain mimetic

    A synthetic tris(hydroxyethyl) benzenetricarboxamide identified by in silico pharmacophore screening as a sub-nanomolar partial agonist of the TrkB neurotrophin receptor, distinguished by neuroprotective efficacy comparable to BDNF in rodent models of Huntington disease, Rett syndrome, traumatic brain injury, and demyelinating injury, with administration predominantly via the intranasal route owing to limited systemic blood-brain barrier penetration.

    Abstract

    LM22A-4, a synthetic 1-N,3-N,5-N-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide of molecular weight 339.34 g/mol, is a small-molecule partial agonist of tropomyosin receptor kinase B (TrkB) originally identified in 2010 by Massa, Yang, Bhatt, and Longo through in silico pharmacophore screening of commercial chemical libraries against a model of the loop II domain of brain-derived neurotrophic factor (BDNF) [1]. The compound activates TrkB-dependent signaling cascades (phospho-TrkB, phospho-Akt, phospho-ERK1/2) in hippocampal and striatal neurons with a functional EC50 of 200 to 500 picomolar for TrkB activation and an IC50 of 47 nanomolar for competitive displacement of BDNF from the TrkB extracellular domain, producing neuronal survival at 80 to 90 percent of maximal BDNF efficacy in fetal hippocampal neuron assays [1]. The compound is approximately 98 percent smaller than the 27 kDa BDNF homodimer, is freely water-soluble, and is stable in aqueous solution at neutral pH, properties that make it operationally attractive as a research tool for investigating TrkB-dependent neurotrophic signaling in vitro and in vivo. A substantial preclinical literature, principally from the laboratories of Frank Longo and Stephen Massa at Stanford University and the University of California San Francisco, has demonstrated that LM22A-4 prevents neuronal degeneration with efficacy comparable to BDNF in multiple in vitro disease models, including amyloid-beta-induced hippocampal neuron death, MPP+-induced dopaminergic cell death (a Parkinson disease model), and quinolinic acid-induced striatal neuron death (a Huntington disease model) [1]. In vivo, LM22A-4 administered intranasally or by combined intraperitoneal and intranasal routes activates TrkB signaling in mouse hippocampus and striatum and produces functional benefit in rodent models of Huntington disease (R6/2 and BACHD transgenic mice) [2], Rett syndrome (MeCP2 mutant mice) [3, 4], pediatric and adult traumatic brain injury [5, 6], spinal cord injury [7], ischemic stroke [8], demyelinating injury (cuprizone model) [9], and nonarteritic anterior ischemic optic neuropathy [10]. The Huntington disease work by Simmons et al. (2013) demonstrated correction of striatal TrkB signaling deficits, reduction of intranuclear huntingtin aggregates, preservation of medium spiny neuron dendritic spine density, and improvement of motor function across both acute (R6/2) and chronic (BACHD) transgenic models at brain concentrations exceeding the in vitro neuroprotective dose [2]. The Rett syndrome work demonstrated acute reversal of spontaneous apneas and respiratory dysregulation in MeCP2-null and heterozygous mice, with 4-week treatment restoring wild-type breathing frequency and TrkB phosphorylation in medullary and pontine respiratory nuclei [3, 4]. A critical pharmacological limitation is poor blood-brain barrier penetration following systemic administration, which has necessitated intranasal delivery for central nervous system applications in essentially all published in vivo studies [1, 2]. The intranasal route bypasses the blood-brain barrier through olfactory and trigeminal nerve pathways, achieving cerebrospinal fluid and brain parenchymal concentrations sufficient for TrkB activation, but poses translational challenges for clinical development. A second limitation, identified by Bai et al. (2010) and extended by Todd et al. (2014) and subsequent investigations, is mechanistic complexity: multiplex quantitative assays suggest that LM22A-4 may not activate TrkB through direct orthosteric agonism but rather through indirect transactivation mediated by an unidentified G-protein coupled receptor and Src-family kinase (most likely Fyn) signaling [11, 12]. Despite this mechanistic debate, TrkB-dependence of the in vivo effects has been confirmed through conditional oligodendroglial TrkB deletion studies [9], and the functional neuroprotective and neuroregenerative outcomes are reproducible across laboratories and disease models. The compound has not entered human clinical trials as of the most recent monograph revision. It is supplied by multiple research chemical vendors at greater than 98 percent purity and is used exclusively as a research tool. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • MitoTEMPO

    Mitochondria-targeted nitroxide antioxidant and superoxide dismutase mimetic

    A triphenylphosphonium-conjugated piperidine nitroxide developed as a mitochondria-selective superoxide scavenger, distinguished from conventional antioxidants by its several-hundred-fold accumulation in energized mitochondria and its established preclinical efficacy across cardiovascular, renal, hepatic, and neurological models of oxidative injury.

    Abstract

    MitoTEMPO (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride) is a mitochondria-targeted superoxide dismutase (SOD) mimetic that combines the piperidine nitroxide TEMPO radical with a lipophilic triphenylphosphonium (TPP+) cation. The TPP+ moiety exploits the large negative-inside mitochondrial membrane potential (approximately 150 to 180 mV) to drive electrophoretic accumulation of the compound across the inner mitochondrial membrane, achieving intramitochondrial concentrations several hundred-fold greater than extracellular concentrations in energized cells [1, 2]. Once localized to the mitochondrial matrix, the nitroxide radical undergoes a catalytic cycle between its oxidized (nitroxide) and reduced (hydroxylamine) forms, dismuting superoxide to hydrogen peroxide and molecular oxygen in a reaction that functionally mimics manganese superoxide dismutase (MnSOD, SOD2) [3]. This SOD-mimetic activity is complemented by alkyl radical scavenging capacity, enabling MitoTEMPO to interrupt lipid peroxidation chain reactions within the mitochondrial inner membrane. The compound was first characterized in a cardiovascular context by Dikalova, Dikalov, and colleagues at Emory University in a 2010 Circulation Research report demonstrating that MitoTEMPO attenuated angiotensin II-induced hypertension in mice at doses 1000-fold lower than the non-targeted parent compound TEMPOL, reduced mitochondrial and total cellular superoxide, restored vascular nitric oxide bioavailability, and improved endothelial-dependent relaxation [1]. This seminal study established MitoTEMPO as a pharmacological tool for dissecting the contribution of mitochondrial reactive oxygen species (mtROS) to disease pathogenesis and stimulated a broad preclinical literature now spanning hypertension, heart failure, ischemia-reperfusion injury, doxorubicin cardiotoxicity, diabetic nephropathy, acetaminophen hepatotoxicity, hepatocarcinogenesis, sepsis-associated acute kidney injury, noise-induced hearing loss, radiation injury, neurodegenerative disease models, and chronic pain. MitoTEMPO has not entered human clinical trials. No regulatory authority has approved it for therapeutic use. The compound remains a research-grade tool, supplied by multiple chemical vendors (Sigma-Aldrich, Cayman Chemical, Selleckchem, MedChemExpress, others) at greater than 98 percent purity by HPLC. Formal pharmacokinetic studies characterizing oral bioavailability, plasma half-life, and metabolic disposition in any species have not been published; the preclinical literature relies on functional endpoints (superoxide reduction, blood pressure attenuation, organ protection) rather than on classical pharmacokinetic parameters. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CDD-0102

    Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class

    A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.

    Abstract

    CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Afobazole

    Selective non-benzodiazepine anxiolytic with sigma-1 receptor chaperone agonism and multi-target neuroprotective activity

    A 2-mercaptobenzimidazole derivative developed at the V.V. Zakusov Research Institute of Pharmacology and registered in Russia as a non-sedating anxiolytic, distinguished from benzodiazepines by absence of dependence liability and from buspirone by sigma-1 receptor chaperone agonism as the principal molecular mechanism.

    Abstract

    Afobazole (INN fabomotizole; development code CM-346; CAS 173352-21-1) is a 2-mercaptobenzimidazole anxiolytic synthesized and pharmacologically characterized at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences under the direction of Academician S.B. Seredenin. The compound was registered in the Russian Federation in 2006 for the treatment of generalized anxiety disorder and adjustment disorders, and was assigned the International Nonproprietary Name fabomotizole by the World Health Organization in 2012. Structurally, afobazole is 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole, a synthetic benzimidazole bearing a thioether-linked morpholine side chain and an ethoxy substituent on the aromatic ring. The molecular formula is C15H21N3O2S (free base, molecular weight 307.41 g/mol), and the compound is supplied pharmaceutically as the dihydrochloride salt (C15H23Cl2N3O2S, molecular weight 380.33 g/mol).

    The pharmacological profile of afobazole is multi-target. Radioligand binding studies have identified the sigma-1 receptor chaperone protein (Sigma1R; Ki approximately 5.9 micromolar), NRH:quinone reductase 2 (NQO2, also designated the MT3 melatonin binding site; Ki approximately 0.97 micromolar), monoamine oxidase A (MAO-A regulatory site; Ki approximately 3.6 micromolar), and the melatonin MT1 receptor (Ki approximately 16 micromolar) as the principal molecular targets [1, 2]. The sigma-1 receptor interaction is the best-characterized mechanism: afobazole acts as a Sigma1R agonist, promoting dissociation of the Sigma1R-BiP complex at the endoplasmic reticulum membrane and downstream modulation of calcium signaling, inositol 1,4,5-trisphosphate receptor function, and expression of neurotrophic factors including nerve growth factor and brain-derived neurotrophic factor [3, 4]. The anxiolytic effect is blocked by selective Sigma1R antagonists (BD-1047, NE-100) in rodent behavioral models, confirming the dependence of the therapeutic activity on Sigma1R engagement [5, 6].

    Pharmacokinetics are characterized by rapid oral absorption (Tmax approximately 0.85 hours), pronounced first-pass hepatic metabolism (oral bioavailability approximately 44 percent), and a short plasma elimination half-life (approximately 0.82 hours) [9]. Despite the short systemic half-life, the anxiolytic effect persists substantially beyond the plasma residence of the parent compound, a pharmacodynamic feature attributed to the slow dissociation kinetics of the Sigma1R chaperone complex and to the sustained expression of downstream neurotrophic mediators.

    The clinical evidence base comprises several Russian multicenter trials. The principal registration study was a randomized, double-blind, active-controlled trial of 150 patients with generalized anxiety disorder or adjustment disorders comparing afobazole (30 mg/day) to diazepam (30 mg/day) for 30 days; afobazole produced greater reduction in Hamilton Anxiety Rating Scale total score than diazepam (mean difference 2.93 points; p = 0.01), with 15 adverse events in the afobazole group versus 199 in the diazepam group, and no withdrawal syndrome on discontinuation [8]. Additional studies have evaluated afobazole in somatoform disorders, irritable bowel syndrome, premenstrual syndrome, alcohol withdrawal, and tobacco cessation, with consistent evidence of anxiolytic efficacy and favorable tolerability [10, 11, 12].

    Preclinical research has extended the pharmacological profile well beyond anxiolysis. Afobazole produces Sigma1R-dependent neuroprotection in rat models of ischemic stroke (middle cerebral artery occlusion), with reduced infarct volume and improved neurological outcomes when administered up to 24 hours post-occlusion [13, 14]. In the 6-hydroxydopamine mouse model of Parkinson’s disease, afobazole at 2.5 mg/kg intraperitoneally for 14 days restored striatal dopamine content, preserved tyrosine hydroxylase-positive neurons in the substantia nigra, and normalized motor coordination; these effects were abolished by the Sigma1R antagonist BD-1047 [15, 16]. Cardioprotective activity has been demonstrated in models of isoproterenol-induced myocardial injury, chronic heart failure, and alcoholic cardiomyopathy, with attenuation of pathological remodeling, preserved inotropic function, and reduced brain natriuretic peptide levels [17, 18, 19]. Angiogenic effects have also been reported [20].

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 7,8-Dihydroxyflavone

    Naturally occurring flavone and selective small-molecule tropomyosin receptor kinase B (TrkB) agonist with BDNF-mimetic neurotrophic activity

    A naturally occurring dihydroxylated flavone identified through cell-based TrkB receptor screening as the first orally bioactive small-molecule brain-derived neurotrophic factor mimetic, distinguished by selective TrkB agonism, blood-brain barrier penetration, and broad preclinical neuroprotective and procognitive efficacy across neurodegenerative, neuropsychiatric, and metabolic disease models.

    Abstract

    7,8-Dihydroxyflavone (7,8-DHF), also designated tropoflavin, is a naturally occurring flavone first isolated from the leaves of Godmania aesculifolia and subsequently identified in Tridax procumbens, Primula vulgaris, and other plant species. The compound was characterized in 2010 by Jang et al. at Emory University as the first orally bioactive, blood-brain-barrier-penetrant small-molecule agonist of the tropomyosin receptor kinase B (TrkB), the principal high-affinity signaling receptor for brain-derived neurotrophic factor (BDNF) [1]. 7,8-DHF binds the extracellular domain of TrkB with a dissociation constant of approximately 320 nM by filter binding assay and approximately 15.4 nM by surface plasmon resonance, triggering receptor dimerization, autophosphorylation at tyrosine residues 706/707, and activation of the downstream PI3K/Akt and MAPK/ERK signaling cascades that mediate neuronal survival, synaptic plasticity, and long-term potentiation [1, 2]. The compound displays selectivity for TrkB over the related neurotrophin receptors TrkA and TrkC and does not activate TrkB kinase-dead mutants, confirming that the phosphorylation signal arises from the receptor itself rather than from off-target tyrosine kinases [2].

    Pharmacokinetic characterization in rodents reveals oral bioavailability of approximately 4.6 percent, a plasma half-life of approximately 134 minutes, rapid brain penetration with peak brain concentrations at 10 minutes after oral dosing, and primary hepatic metabolism through glucuronidation, sulfation, and catechol-O-methyltransferase-mediated methylation [3, 4]. The O-methylated metabolites (7-methoxy-8-hydroxyflavone and 7-hydroxy-8-methoxyflavone) retain TrkB agonist activity in vitro and in vivo, extending the effective pharmacodynamic window beyond the parent compound [5]. The modest oral bioavailability prompted the development of the prodrug R13 (a carbamate ester derivative) by the Ye laboratory, which increases oral bioavailability to approximately 10.5 percent and extends the plasma half-life to approximately 220 minutes [6]. R13 has entered Phase 1 clinical evaluation for Alzheimer’s disease, representing the most advanced clinical translation of TrkB agonist pharmacology from this scaffold.

    Preclinical pharmacology is extensive. In Parkinson’s disease models, the compound protects dopaminergic neurons from MPTP- and rotenone-induced degeneration and improves motor function [10]. In depression models, 7,8-DHF reverses learned helplessness, chronic mild stress, and social defeat stress phenotypes through restoration of hippocampal and prefrontal cortical TrkB-BDNF signaling [11, 12]. Additional preclinical efficacy has been demonstrated in models of Huntington’s disease, amyotrophic lateral sclerosis, traumatic brain injury, post-traumatic stress disorder, Rett syndrome, fragile X syndrome, retinal ganglion cell degeneration, and diet-induced obesity [13, 14, 15, 16, 17, 18, 19].

    A 7-month oral dosing study in a non-human primate model of Parkinson’s disease similarly reported no toxic reactions [20]. No human clinical trial data for the parent compound 7,8-DHF have been published; clinical development has proceeded through the prodrug R13. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • P7C3-A20

    Aminopropyl carbazole neuroprotective agent functioning as a nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulator

    A synthetic 3,6-dibromocarbazole derivative discovered through target-agnostic in vivo neurogenesis screening, distinguished by its activation of the NAD+ salvage enzyme NAMPT and broad neuroprotective efficacy across preclinical models of traumatic brain injury, ischemic stroke, Parkinson disease, amyotrophic lateral sclerosis, and Alzheimer disease.

    Abstract

    P7C3-A20, the fluorinated and methoxylated analog of the parent aminopropyl carbazole P7C3, is a synthetic neuroprotective compound identified through iterative structure-activity optimization of a chemical series originally discovered in a target-agnostic in vivo screen for enhancers of adult hippocampal neurogenesis conducted by Pieper, McKnight, and colleagues at the University of Texas Southwestern Medical Center [1]. The parent compound P7C3 was one of eight hits from a library of approximately 1,000 small molecules screened for their ability to augment the survival of newborn neurons in the subgranular zone of the murine dentate gyrus. Subsequent medicinal chemistry optimization, principally the replacement of the central hydroxyl with fluorine and the introduction of a methoxy substituent on the aniline ring, yielded P7C3-A20, which demonstrated approximately ten-fold greater proneurogenic potency than the parent compound while retaining favorable oral bioavailability, blood-brain barrier penetration, and tolerability in chronic dosing studies in rodents and nonhuman primates [2, 3]. The molecular target of P7C3-A20 was identified by Wang et al. (2014) as nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway [4]. P7C3-A20 functions as a positive allosteric modulator of NAMPT, enhancing the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and thereby augmenting intracellular NAD+ levels under conditions of metabolic stress without elevating NAD+ to supraphysiologic concentrations. This mechanism distinguishes P7C3-A20 from direct NAD+ precursor supplementation strategies (nicotinamide riboside, nicotinamide mononucleotide) by preserving endogenous feedback regulation of the salvage pathway. The downstream consequences of NAMPT activation and NAD+ restoration include maintenance of sirtuin deacetylase activity (particularly SIRT1 and SIRT3), protection of mitochondrial bioenergetics, suppression of oxidative stress and DNA damage, attenuation of neuroinflammation through microglial modulation, and enhancement of the survival of newly generated neurons during adult hippocampal neurogenesis. The preclinical pharmacology of P7C3-A20 has been characterized across an unusually broad spectrum of neurodegenerative and neurotraumatic disease models. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease, P7C3-A20 substantially preserved dopaminergic neurons in the substantia nigra [5]. In the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis (ALS), P7C3-A20 reduced motor neuron cell death in the spinal cord [6]. In models of traumatic brain injury (TBI), P7C3-A20 blocked axonal degeneration and preserved neurological function when administered acutely [7], and, in a landmark 2020 study, restored blood-brain barrier integrity, arrested chronic neurodegeneration, and recovered normal cognitive function when treatment was initiated a full twelve months after the initial injury [8]. In rat models of focal ischemic stroke, P7C3-A20 promoted post-ischemic neurogenesis, restored cortical NAD+ levels, and improved chronic sensorimotor and cognitive outcomes [9]. In retinal degeneration models, the P7C3 class protected retinal ganglion cells from optic nerve injury [10]. In 2025, Vazquez-Rosa et al. published a study in Cell Reports Medicine demonstrating that P7C3-A20 treatment of 5xFAD and PS19 transgenic mice with advanced Alzheimer-like pathology produced comprehensive reversal of tau phosphorylation, blood-brain barrier deterioration, oxidative stress, DNA damage, and neuroinflammation, with full cognitive recovery and normalization of the clinical biomarker p-tau217 [11]. P7C3-A20 has not entered human clinical trials as of the most recent monograph revision. The compound is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at high purity. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.